Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 12;11(11):3035.
doi: 10.3390/biomedicines11113035.

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy

Magdalena Złotek  1 , Antonina Kurowska  1 , Mariola Herbet  1 , Iwona Piątkowska-Chmiel  1
Affiliations
Review

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy

Magdalena Złotek et al. Biomedicines. .

Abstract

Alzheimer's is a prevalent, progressive neurodegenerative disease marked by cognitive decline and memory loss. The disease's development involves various pathomechanisms, including amyloid-beta accumulation, neurofibrillary tangles, oxidative stress, inflammation, and mitochondrial dysfunction. Recent research suggests that antidiabetic drugs may enhance neuronal survival and cognitive function in diabetes. Given the well-documented correlation between diabetes and Alzheimer's disease and the potential shared mechanisms, this review aimed to comprehensively assess the potential of new-generation anti-diabetic drugs, such as GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, as promising therapeutic approaches for Alzheimer's disease. This review aims to comprehensively assess the potential therapeutic applications of novel-generation antidiabetic drugs, including GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, in the context of Alzheimer's disease. In our considered opinion, antidiabetic drugs offer a promising avenue for groundbreaking developments and have the potential to revolutionize the landscape of Alzheimer's disease treatment.

Keywords: Alzheimer’s disease; DPP-4 inhibitors; GLP-1 analogs; SGLT-2 inhibitors; antidiabetic drugs; neuroprotection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Metabolic and molecular similarities between type 2 diabetes and Alzheimer’s disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nguyen T.T., Nguyen T.T.D., Nguyen T.K.O., Vo T.K. Advances in developing therapeutic strategies for Alzheimer’s disease. Biomed. Pharmacother. 2021;139:111623. doi: 10.1016/j.biopha.2021.111623. - DOI - PubMed
    1. Zhang X.X., Tian Y., Wang Z.T., Ma Y.H., Tan L., Yu J.T. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J. Prev. Alzheimers Dis. 2021;8:313–321. doi: 10.14283/jpad.2021.15. - DOI - PubMed
    1. Clark K., Leung Y.Y., Lee W.P., Voight B., Wang L.S. Polygenic risk scores in Alzheimer’s disease genetics: Methodology, applications, inclusion, and diversity. J. Alzheimers Dis. 2022;89:1–12. doi: 10.3233/JAD-220025. - DOI - PMC - PubMed
    1. Silva M.V.F., Loures C.D.M.G., Alves L.C.V., de Souza L.C., Borges K.B.G., Carvalho M.D.G. Alzheimer’s disease: Risk factors and potentially protective measures. J. Biomed. Sci. 2019;26:33. doi: 10.1186/s12929-019-0524-y. - DOI - PMC - PubMed
    1. Dave B.P., Shah Y.B., Maheshwari K.G., Mansuri K.A., Prajapati B.S., Postwala H.I., Chorawala M.R. Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer’s Disease: Recent Trends and Future Development. Cell. Mol. Neurobiol. 2023:1–38. doi: 10.1007/s10571-023-01408-7. - DOI - PMC - PubMed

LinkOut - more resources